Chlamydia and Borrelia DNA in synovial fluid of patients with early undifferentiated oligoarthritis: results of a prospective study.
OBJECTIVE
More than 50% of patients with synovitis involving 1-4 joints remain classified as having undifferentiated oligoarthritis (UOA) after 1 year of disease. The clinical presentation is often similar to that of reactive arthritis (ReA) and other spondylarthropathies or to Lyme arthritis. We therefore determined how often Chlamydia trachomatis (Ct) and Borrelia burgdorferi (Bb) can be identified in patients with UOA, by using an extensive laboratory approach.


METHODS
We prospectively studied 52 patients with UOA who presented at an early synovitis clinic in a region highly endemic for Lyme disease. Patients were examined by standardized clinical and immunoserologic procedures. Synovial fluid was screened for the presence of Ct and Bb DNA by polymerase chain reaction (PCR). Urine was tested for Ct DNA by ligase chain reaction, and serum was tested for Ct antibodies by enzyme-linked immunosorbent assay and Bb antibodies by hemagglutination test and Western blotting. PCR results in the UOA patients were compared with the results in cohorts of patients with definite rheumatoid arthritis (RA), Lyme arthritis, and Chlamydia-induced arthritis (CIA).


RESULTS
In the synovial fluid of 9 of 52 patients with UOA (17%), we found Ct DNA, and in 6 of the 52 patients (12%), Bb DNA was found. The frequency of bacteria-specific DNA was 50% (7 of 14) in CIA patients and 69% (11 of 16) in patients with Lyme arthritis. No Bb or Ct DNA was found in the synovial fluid of the 31 RA patients.


CONCLUSIONS
With optimized PCR protocols, it is possible to detect considerable levels of Bb and Ct DNA in the synovial fluid of patients with UOA. Although the presence of bacterial DNA does not unequivocally prove its etiologic significance, we suggest that at least one-third of patients with UOA may have a form of ReA that involves asymptomatic primary infection.
Schnarr
S
S
Hannover Medical School, Division of Rheumatology, Germany. schnarr.sebastian@mh-hannover.de
Putschky
N
N
Jendro
M C
MC
Zeidler
H
H
Hammer
M
M
Kuipers
J G
JG
Wollenhaupt
J
J
D000293:Adolescent; D000328:Adult; D001168:Arthritis / Q000175:diagnosis* / Q000209:etiology; D016918:Arthritis, Reactive / Q000175:diagnosis / Q000209:etiology; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000209:etiology; D025065:Borrelia burgdorferi / Q000235:genetics / Q000302:isolation & purification*; D002690:Chlamydia Infections / Q000175:diagnosis / Q000209:etiology; D002692:Chlamydia trachomatis / Q000235:genetics / Q000302:isolation & purification*; D004269:DNA, Bacterial / Q000032:analysis*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008193:Lyme Disease / Q000150:complications / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D000091402:Prohibitins; D011446:Prospective Studies; D013582:Synovial Fluid / Q000737:chemistry / Q000382:microbiology*; D013585:Synovitis / Q000209:etiology / Q000382:microbiology
D004269:DNA, Bacterial; C000717331:PHB2 protein, human; D000091402:Prohibitins